Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

被引:512
作者
Clark, James D. [1 ]
Flanagan, Mark E. [2 ]
Telliez, Jean-Baptiste [1 ]
机构
[1] Pfizer Immunosci, Cambridge, MA 02140 USA
[2] Pfizer Inc, Ctr Chem Innovat & Excellence, Groton, CT 06340 USA
关键词
MODIFYING ANTIRHEUMATIC DRUGS; STRUCTURE-BASED DESIGN; TYROSINE KINASE; PSEUDOKINASE DOMAIN; HIGH SELECTIVITY; PROTEIN-KINASE; RODENT MODELS; POTENT; ARTHRITIS; CP-690,550;
D O I
10.1021/jm401490p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnology industries as therapeutic targets. Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications. Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.
引用
收藏
页码:5023 / 5038
页数:16
相关论文
共 101 条
[1]  
[Anonymous], 2013, MED LETT DRUGS THER, V55, P1
[2]  
[Anonymous], 2012, NAT REV DRUG DISCOV, V11, P895, DOI DOI 10.1038/NRD3911
[3]   Hematopoietic cytokine receptor signaling [J].
Baker, S. J. ;
Rane, S. G. ;
Reddy, E. P. .
ONCOGENE, 2007, 26 (47) :6724-6737
[4]   Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders [J].
Basquiera, Ana L. ;
Soria, Nestor W. ;
Ryser, Ricardo ;
Salguero, Miriam ;
Moiraghi, Beatriz ;
Sackmann, Federico ;
Sturich, Ana G. ;
Borello, Adriana ;
Berretta, Adriana ;
Bonafe, Miriam ;
Moreno Barral, Jose ;
Palazzo, Emilio D. ;
Garcia, Juan J. .
HEMATOLOGY, 2009, 14 (06) :323-330
[5]  
Belli B., 2010, ARTHRITIS S10, V62, P269
[6]   Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog [J].
Boggon, TJ ;
Li, YQ ;
Manley, PW ;
Eck, MJ .
BLOOD, 2005, 106 (03) :996-1002
[7]   Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis [J].
Boy, Mary G. ;
Wang, Cunshan ;
Wilkinson, Bethanie E. ;
Chow, Vincent Fung-Sing ;
Clucas, Alan T. ;
Krueger, James G. ;
Gaweco, Anderson S. ;
Zwillich, Samuel H. ;
Changelian, Paul S. ;
Chan, Gary .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (09) :2299-2302
[8]  
Bristol-Myers Squibb Co, 2011, JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer, Patent No. [WO 2010010190 A1, 2010010190, WO2011028864]
[9]   Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients [J].
Busque, S. ;
Leventhal, J. ;
Brennan, D. C. ;
Steinberg, S. ;
Klintmalm, G. ;
Shah, T. ;
Mulgaonkar, S. ;
Bromberg, J. S. ;
Vincenti, F. ;
Hariharan, S. ;
Slakey, D. ;
Peddi, V. R. ;
Fisher, R. A. ;
Lawendy, N. ;
Wang, C. ;
Chan, G. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (08) :1936-1945
[10]   Inborn Errors of Human JAKs and STATs [J].
Casanova, Jean-Laurent ;
Holland, Steven M. ;
Notarangelo, Luigi D. .
IMMUNITY, 2012, 36 (04) :515-528